China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche
17/10/2025 24:28
Oct 17 (Reuters) - Chinese biotech Hansoh Pharma 3692.HK said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's ROG.S subsidiary for an investigational treatment of colorectal cancer and other solid tumors. (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber) ((Sneha.Kumar@thomsonreuters.com))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion